BioAtla (BCAB) Operating Income (2020 - 2026)
BioAtla's (BCAB) quarterly Operating Income came in at $227000.0 in Q2 2026, up 101.22% on a YoY basis from $112813.3 in Q2 2025, and up 102.44% quarter-over-quarter from -$9.3 million in Q1 2026.
Analysis
BioAtla (BCAB) Operating Income (2020 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Operating Income for 7 consecutive years, with $227000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Income rose 101.22% year-over-year to $227000.0; the trailing twelve-month figure through Jun 2026 stood at -$32.1 million (up 49.63% YoY), and the FY2025 full-year result was -$59.3 million, up 19.8% from the prior year.
- Operating Income grew to $227000.0 in Q2 2026 per BCAB's latest filing, from -$9.3 million in the prior quarter.
- Across five years, Operating Income topped out at $227000.0 in Q2 2026 and bottomed at -$37.2 million in Q2 2023.
- Historically, Operating Income has averaged -$21.1 million across 5 years, with a median of -$23.2 million in 2022.
- The sharpest annual moves came in 2023 and 2026: Operating Income slumped 33.77% in 2023, then soared 101.22% in 2026.
- Over 5 years, Operating Income stood at -$28.6 million in 2022, then gained by 0.08% to -$28.5 million in 2023, then jumped by 43.08% to -$16.2 million in 2024, then soared by 43.03% to -$9.3 million in 2025, then surged by 102.45% to $227000.0 in 2026.
- According to Business Quant data, Operating Income over the past three periods registered $227000.0, -$9.3 million, and -$9.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -365.99 Mn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | 227,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 227,000.00 |
| Mar 31, 2026 | -9.31 Mn |
| Dec 31, 2025 | -9.26 Mn |
| Sep 30, 2025 | -13.79 Mn |
| Jun 30, 2025 | -18.65 Mn |
| Mar 31, 2025 | -17.61 Mn |
| Dec 31, 2024 | -16.24 Mn |
| Sep 30, 2024 | -11.27 Mn |
| Jun 30, 2024 | -21.97 Mn |
| Mar 31, 2024 | -24.46 Mn |
| Dec 31, 2023 | -28.54 Mn |
| Sep 30, 2023 | -35.02 Mn |
| Jun 30, 2023 | -37.20 Mn |
| Mar 31, 2023 | -28.93 Mn |
| Dec 31, 2022 | -28.56 Mn |
| Sep 30, 2022 | -26.18 Mn |
| Jun 30, 2022 | -29.06 Mn |
| Mar 31, 2022 | -24.35 Mn |
| Dec 31, 2021 | -23.49 Mn |
| Sep 30, 2021 | -23.70 Mn |